Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01494233 is registered in ClinicalTrials.gov with Lexicon Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
- Lead sponsor
- Lexicon Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 29, 2012
- Completion date
- Not reported
- Enrollment
- 373 (actual)
- Sites
- 81
Conditions
As the registry lists them; a condition with its own page is linked.